Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
Alternative names
ker-050 (2 trials)
ruxolitinib (jakafi) (1 trial)
Myelodysplastic Syndromes (Phase 2)
Preleukemia (Phase 2)
Syndrome (Phase 2)
Trials (2 total)
Trial APIs (2 total)